List of Orladeyo drug patents
Orladeyo is owned by Biocryst.
Orladeyo contains Berotralstat Hydrochloride.
Orladeyo has a total of 6 drug patents out of which 0 drug patents have expired.
Orladeyo was authorised for market use on 03 December, 2020.
Orladeyo is available in capsule;oral dosage forms.
Orladeyo can be used as prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older, prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older.
Drug patent challenges can be filed against Orladeyo from December, 2024.
The generics of Orladeyo are possible to be released after 01 November, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(12 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 3, 2027 |
| New Chemical Entity Exclusivity (NCE) | Dec 3, 2025 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: December, 2024
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic